Every 8-K that MoonLake Immunotherapeutics (MLTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MLTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MLTX filings page.
MoonLake Immunotherapeutics reported new clinical and financial updates. The company announced that the Phase 3 IZAR-1 trial of sonelokimab 60 mg with induction in biologic-naïve adults with psoriatic arthritis met all clinical endpoints at Week 16. A total of 42.1% of patients achieved an ACR50 response, with 66.5% achieving ACR20, 41.2% reaching Minimal Disease Activity, and 61% of patients with skin involvement achieving PASI90. Patient-reported and functional measures improved, including a mean HAQ-DI change of -0.427 and an SF-36 PCS score change of 6.54, and the blinded safety analysis showed no new safety signals.
For the quarter ended June 30, 2026, MoonLake reported a net loss of $61.8 million, or $0.84 per share, compared with a net loss of $69.7 million in the prior quarter. Research and development expenses were $50.2 million and general and administrative expenses were $11.4 million, both lower than the previous quarter. The company held $537.0 million in cash, cash equivalents and short-term marketable debt securities as of June 30, 2026, and expects this to fund operations into mid-2028, supplemented by a Hercules Capital debt facility of up to $400 million.
MoonLake Immunotherapeutics reported that underwriters in its previously announced public offering exercised in full their option to purchase an additional 1,500,000 Class A ordinary shares on July 10, 2026. The sale of these Option Shares generated $30.0 million in additional gross proceeds, before underwriting discounts, commissions and offering expenses. The issuance and sale of the Option Shares closed on July 14, 2026.
MoonLake Immunotherapeutics entered an underwriting agreement for a $200 million equity offering. The company agreed to sell 9,000,000 Class A ordinary shares at $20.00 per share and, for certain investors, pre-funded warrants to purchase up to 1,000,000 ordinary shares at a public offering price of $19.9999 each with a nominal exercise price of $0.0001.
The underwriters also have a 30-day option to buy up to an additional 1,500,000 ordinary shares at the public offering price less underwriting discounts and commissions. The securities are being issued under an effective Form S-3 shelf registration, with closing expected on June 25, 2026, subject to customary conditions.
MoonLake Immunotherapeutics reported final Week 52 Phase 3 VELA data for its Nanobody sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa, plus interim Phase 3 VELA-TEEN results in adolescents. Across VELA-1 and VELA-2, 67.2% of adults on SLK achieved HiSCR75 and 33.1% reached HiSCR100 at Week 52 (n=396), with 26.0% achieving IHS4-100 inflammatory remission. Patient-reported outcomes improved meaningfully, including large HiSQOL and DLQI gains and pain reduction in 46.5% of eligible adults. In VELA-TEEN, approximately 68% of adolescents achieved HiSCR75 and ~45% achieved HiSCR100 at Week 24 (n=22), with no new safety signals. MoonLake plans to submit a BLA for HS at the end of September 2026 and expects BLA acceptance and PDUFA date notification by the end of November 2026, with Priority Review viewed as an upside case.
MoonLake Immunotherapeutics held its 2026 Annual General Meeting of Shareholders, where investors approved all proposals, including amendments to the 2022 Equity Incentive Plan. The plan now adds 5,000,000 Class A ordinary shares for stock-based awards and extends its term to June 4, 2036.
Other changes to the plan include removing liberal share recycling, adding a one-year minimum vesting requirement, revising non-employee director compensation limits, and clarifying treatment of awards upon a change in control. Shareholders also re-elected Class I director Spike Loy, ratified Baker Tilly US, LLP as independent auditor, and approved the advisory vote on executive compensation.
MoonLake Immunotherapeutics has entered into a Master Commercial Supply Agreement with Vetter Pharma International, under which Vetter will manufacture pre-filled application systems containing an active drug, placebo or other material, supporting MoonLake’s product pipeline, including its sonelokimab program.
The agreement uses product-specific schedules that set detailed services and pricing, which Vetter may adjust over time based on documented changes in its cost structure. It remains in force until terminated, with rights for either party to end it for uncured material breach, insolvency, certain change-of-control events or, in some cases, on 12 months’ written notice.
MoonLake and Vetter also signed a separate Capacity Agreement that requires MoonLake to commit to minimum and maximum annual demand levels. Vetter will reserve filling capacity for this Maximum Quantity, while MoonLake may owe capacity compensation or a share of lost net revenue if orders fall below the agreed Minimum Quantity or forecast period.
MoonLake Immunotherapeutics reported a larger net loss but also a key regulatory milestone for its lead drug sonelokimab. For the quarter ended March 31, 2026, the company posted a net loss of $69.7 million, or $0.98 per share, on operating expenses of $70.0 million.
MoonLake ended the quarter with $357.9 million in cash, cash equivalents and short-term marketable debt securities and expects this to fund operations to the end of 2027, supplemented by up to $400 million available from a debt facility. Total assets were $400.4 million and shareholders’ equity was $254.0 million.
The FDA gave a positive outcome in the final pre-BLA meeting for sonelokimab in hidradenitis suppurativa, agreeing on submission plans, label strategy and use of MIRA and VELA-TEEN data. MoonLake plans to submit a Biologics License Application by the end of September 2026, with a potential first U.S. launch in the second half of 2027 if approved.
MoonLake Immunotherapeutics entered into an amended senior secured term loan facility totaling $500.0 million with Hercules Capital, drawing $25.0 million and leaving up to $400.0 million of additional non-dilutive funding available across future tranches tied to clinical, regulatory and market-cap milestones.
The amended agreement adds a conditional revenue covenant if the fifth tranche is used, but has no scheduled amortization and allows full prepayment with declining fees. MoonLake also reported positive Phase 2 S-OLARIS data in axial spondyloarthritis, with 81% of sonelokimab-treated patients achieving an ASAS40 response at week 12 and more than 80% showing clinically important ASDAS-CRP improvement, supported by MRI, PET and biomarker data, and a safety profile consistent with prior trials.
As of December 31, 2025, the company held $394.0 million in cash, cash equivalents and short-term marketable debt securities and expects this to fund operations and capital needs into the second half of 2027. Director Simon Sturge will resign effective February 28, 2026, with Jorge Santos da Silva becoming Interim Chair and Spike Loy appointed Lead Independent Director.
MoonLake Immunotherapeutics reported that it received positive feedback from the U.S. Food and Drug Administration on the clinical evidence strategy for its drug candidate Sonelokimab (SLK) in hidradenitis suppurativa, following a requested Type B FDA meeting. This feedback relates to how the company is generating the clinical data needed to support SLK in this indication.
The company also plans to hold an Investor Day on February 23, 2026 at 8:00 a.m. Eastern Time to discuss the outcomes of the Type B FDA meeting in more detail and to present new clinical data for SLK across multiple indications. A press release with these updates was filed as an exhibit to this report.
MoonLake Immunotherapeutics entered an underwriting agreement to sell 7,142,857 Class A ordinary shares at $10.50 per share. The transaction is expected to generate gross proceeds of $75 million before underwriting discounts and offering expenses.
The shares are being issued under an effective Form S-3 shelf (File No. 333-274286), with a prospectus supplement dated November 5, 2025. Closing is expected on November 6, 2025, subject to customary closing conditions. The company agreed to customary indemnification provisions in favor of the underwriter, Leerink Partners LLC.
MoonLake Immunotherapeutics furnished an 8-K announcing a press release with its financial results for the quarter ended September 30, 2025 and clinical program updates. Under Item 2.02, the company reported Q3 2025 results via Exhibit 99.1. Under Item 7.01, it highlighted results from the Phase 2 LEDA trial of Sonelokimab (SLK) in adult palmoplantar pustulosis and an interim analysis from the Phase 3 VELA-TEEN trial in adolescents with hidradenitis suppurativa. The Item 7.01 information is being furnished and is not deemed filed under Section 18.
MoonLake Immunotherapeutics reported that it has released week 16 results from its Phase 3 VELA-1 and VELA-2 trials, which are part of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin disease. These late-stage studies are important because they test whether the company’s therapy can provide meaningful benefit in a difficult-to-treat population.
The company issued a press release with the data on September 28, 2025 and scheduled a webcast on September 29, 2025 at 8:00 a.m. Eastern Time to review the results. The press release detailing the clinical data has been filed as an exhibit to this report, giving investors and clinicians access to the full outcome of the VELA-1 and VELA-2 trials.